Efgartigimod
Efgartigimod 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为AChR-Ab Seropositive Generalized Myasthenia Gravis、Myasthenia Gravis、MG、gMG。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
11 项
已进入 III/IV 期
28 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- argenx
- Janssen Research & Development, LLC
- Centre Hospitalier Universitaire de Nice
- Clinique Neuro-Outaouais
- Thomas Jefferson University
- TG Therapeutics, Inc.
- Beijing Tongren Hospital
- University of Colorado, Denver
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
法国、意大利、加拿大、美国、德国、西班牙、比利时、Greece、日本、Poland、澳大利亚、Czechia
正在招募患者的 Efgartigimod 研究
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
IV 期招募中法国NCT07072988A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
不适用招募中意大利NCT07595653Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
III 期招募中加拿大NCT06765161VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)
II 期 / III 期招募中美国NCT07860021A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
不适用招募中美国德国意大利西班牙NCT06299748ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
不适用招募中美国比利时德国GreeceNCT07294170A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
II 期 / III 期招募中美国澳大利亚比利时加拿大NCT06392386A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
II 期招募中美国NCT07673744A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
IV 期招募中美国NCT06909214ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
II 期招募中美国Greece西班牙NCT07673627ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
II 期招募中美国比利时德国GreeceNCT07284420Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
不适用招募中美国德国NCT07264426A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
III 期招募中美国GeorgiaNCT07570316Efgartigimod in Anti-NMDA Receptor Encephalitis.
II 期招募中中国NCT07822776A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
不适用招募中美国奥地利比利时德国NCT06298565Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
III 期招募中美国Israel瑞士NCT07217587A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
II 期 / III 期招募中法国德国意大利日本NCT07194850A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
III 期招募中美国奥地利Bulgaria中国NCT06544499Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
IV 期招募中美国NCT06860633A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
II 期招募中美国NCT06831058A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
III 期招募中比利时Bulgaria加拿大丹麦NCT07596849Efgartigimod for the Treatment of Acute Optic Neuritis
II 期招募中美国NCT06453694
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。